Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its ...

Pfizer's strength lies in its integrated approach to drug development, from discovery to clinical trials, and finally, ...

Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn more about PFE stock here.

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer stands as one of the largest drug makers in the world. It faces normal industry challenges, but it also has a lofty payout ratio. Its latest acquisition shows what it is capable of doing to get ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...